Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.
about
Anti-hepatitis C virus drugs and kidneyLong-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry.Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionEarly Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation.Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantationEffect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomesDo we really need more evidence to use hepatitis C positive donor kidney more liberally?Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.Hepatitis C Virus Infection in Chronic Kidney Disease.Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.Malignancies in hepatitis C virus-positive and -negative kidney transplant recipients: A case-controlled study.Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.Assessment of 4 Cases of Kidney Transplantation from Hepatitis C Virus Antibody-Positive and RNA-Negative Donors to Antibody-Negative Recipients.Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney TransplantationAn update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines.Long-term Patient and Graft Survival of Kidney Transplant Recipients with Hepatitis C Virus Infection in the United States.When and how can nephrologists treat hepatitis C virus infection in dialysis patients?Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios.Successful Treatment of Hepatitis C Virus Genotype 4 in Renal Transplant Recipients With Direct-Acting Antiviral Agents.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is Over.Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.Transplant glomerulopathy.Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients.Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center.Hepatitis C and renal transplantation in era of new antiviral agentsPrevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
P2860
Q28070279-151B7022-2839-4568-9D7E-AAECD39F64BAQ31136569-079D1EC3-2C70-4921-8D50-A0BF29919CA2Q36077546-F2A10ABE-D527-40F2-B26C-D7175183377AQ37527974-2F86CEC0-896E-452E-AF42-D8285C8CBE89Q37628539-DAD61938-BCE0-4D57-A12D-A4F7332DE752Q38602837-F7ABA6E4-ED54-44E6-8B3C-8EA8CFE308D8Q38611051-BB83A987-1968-4F5E-B5AB-3229C8C84399Q38677150-FAA36746-AE96-43FA-875E-5B5BF24BF684Q38786027-DD5A1947-693A-4A35-ADA1-BD1C65D39462Q38812607-9C2790DF-AF1A-4D49-929F-C8AEFC839A67Q38975165-4AE9DDCC-BCAB-4BFB-BCA1-9D1793332AD1Q39455853-FB4BC9AC-F9C9-4595-87FC-F534C6EC48C5Q39749560-4DA57433-EE66-46F5-8BC3-7119DB085C39Q40051223-C404CDAC-E480-4785-BAC1-B3EE029BA4F9Q40107697-C8214BF4-65B0-479D-A3C8-700AD4642AC2Q40145496-7120175B-3388-4FB3-94AF-D8C4BEA42B64Q40171525-D51F544D-ADA9-46A6-9F3A-FE8169C9BD61Q40199766-966E3BE1-326B-4168-AC4B-7856DB4EEACAQ40278746-E93384D9-5C49-4B63-BC71-AB23FF6F44DFQ40316547-350C9373-8049-4CBA-86D0-9AD4D2D565F8Q40382744-A54BD86F-7342-4AAB-968D-FA473CAC9710Q40423982-A7159A93-9BF8-4467-9A33-63EAF2DE27ADQ40504412-EB04C064-7434-4980-A77C-49AC4CD34BC6Q40598416-74B178FB-C122-4D1C-A6B6-6930CD725411Q40744451-6000FD38-BEF5-4533-8952-3C8BF6EF9690Q41924793-9BDB8996-F9C5-4298-8496-1DBD112F819FQ41934901-5C560CE8-0C60-46AB-B488-4E5C985DF95EQ42370354-F9BADDD2-4E61-4478-8B55-1764A2527691Q42640856-D8B51C44-0427-471B-BCBF-47BB38DB5E7FQ44537942-713C4BC4-7FEB-4F82-9782-5FD4B0E65498Q45325791-9EB696CF-22EC-418F-BE98-74A27BB2C99EQ46080993-9E62A3C1-D5D9-45A5-883A-8FA94543D914Q48302077-3B6117E5-5778-42B4-B7BD-07DF3BF8DFE8Q50063069-5CB91F9F-1C76-46F1-A77D-F76FC3782F50Q55191989-C4C9D018-DB06-40DD-B00D-880E7D1DB273Q55353924-1C0865A3-5517-446F-B9B8-46E1A95563E0Q58792851-B82EA9D7-535C-4593-9C78-0C155BA7FB77Q59126211-D193FEB2-262C-4E7B-8A75-6D8ABB105BDA
P2860
Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Successful Treatment of Hepati ...... irect-Acting Antiviral Agents.
@en
type
label
Successful Treatment of Hepati ...... irect-Acting Antiviral Agents.
@en
prefLabel
Successful Treatment of Hepati ...... irect-Acting Antiviral Agents.
@en
P2093
P2860
P356
P1476
Successful Treatment of Hepati ...... irect-Acting Antiviral Agents.
@en
P2093
D Sawinski
J Trofe-Clark
M Bleicher
P2860
P304
P356
10.1111/AJT.13620
P407
P577
2015-11-25T00:00:00Z